Sign in

Private company

Calithera Biosciences, Inc.

Calithera Biosciences, Inc. is an American pharmaceutical preparations company based in South San Francisco.2

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersSouth San Francisco, United States2
  • Incorporated inDE3
  • Business address343 Oyster Point Blvd #200, South San Francisco, Ca 940803
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI54930042TDFRLM4C8X192
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O The Corporation Trust Company, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 47972342

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-1183.9%Operating margin4
-1180.4%Net margin4
-1373.0%Return on equity4
-$66.4MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Other costs100¢$9.8M

Out of $9.8M in revenue.4 The company lost money this year.

Financial statements

Revenue564$9.8M in 2021−62% since 2017
0$10.0M$20.0M$30.0M2017: $26.0M$26.0M20172018: $22.3M$22.3M2018−14%2021: $9.8M$9.8M2021−56%
Operating income75684-$115.4M in 2021+201% since 2016
-$150.0M-$100.0M-$50.0M02016: -$38.3M-$38.3M20162017: -$29.7M-$29.7M2017−23%2018: -$57.3M-$57.3M2018+93%2019: -$92.9M-$92.9M2019+62%2020: -$91.4M-$91.4M2020−2%2021: -$115.4M-$115.4M2021+26%
Net income75684-$115.1M in 2021+203% since 2016
-$150.0M-$100.0M-$50.0M02016: -$38.0M-$38.0M20162017: -$27.8M-$27.8M2017−27%2018: -$54.6M-$54.6M2018+96%2019: -$89.9M-$89.9M2019+64%2020: -$90.1M-$90.1M2020+0%2021: -$115.1M-$115.1M2021+28%
Fiscal year201620172018201920202021
Revenue$26.0M5$22.3M6$9.8M4
Research and development$27.7M7$43.1M5$66.2M6$76.3M6$71.0M6
Operating expenses$125.2M4
Operating income-$38.3M7-$29.7M5-$57.3M6-$92.9M8-$91.4M4-$115.4M4
Income before tax-$115.1M4
Income tax$07$05$06$08$04$04
Net income-$38.0M7-$27.8M5-$54.6M6-$89.9M8-$90.1M4-$115.1M4
Earnings per share-$26.204-$31.164
Earnings per share (diluted)-$26.204-$31.164
Shares (weighted, basic)3.7M shares4
Shares (weighted, diluted)3.7M shares4

Compare Calithera Biosciences, Inc. with another company

Corporate structure

Calithera Biosciences, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Calithera Biosciences, Inc.

  • Calithera Biosciences, Inc. South San Francisco, California, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Calithera Biosciences, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$4.0M4 Dec 31, 2022$3.9M4 Dec 31, 2021+3.0%
Accumulated depreciation$3.5M4 Dec 31, 2022$3.3M4 Dec 31, 2021+7.3%
Property and equipment, net$434.0K4 Dec 31, 2022$556.0K4 Dec 31, 2021−21.9%
Operating-lease assets (leased space)$1.3M4 Dec 31, 2022$2.5M4 Dec 31, 2021−45.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$25.5M4 Dec 31, 2022$59.5M4 Dec 31, 2021−57.3%
Debt securities available for sale$25.1M4 Dec 31, 2022$56.3M4 Dec 31, 2021−55.5%

Leadership

Who has led Calithera Biosciences, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Susan Molineaux2014–2023

President

  1. Susan Molineaux2014–2023

Chief financial officer

  1. William D. Waddill2014–2016
201520202025
Board members and other officers (19)

Timeline

  1. Jan 25, 20238-K Listing notice or transfer33
  2. Jan 9, 20238-K Exit or restructuring costs; Executive or director change34
  3. Nov 14, 20228-K Results of operations35
  4. Sep 29, 20228-K Ended a material agreement36
  5. Aug 15, 20228-K Results of operations37
  6. Jun 14, 20228-K Bylaws or fiscal year changed38
  7. Jun 3, 20228-K Shareholder vote39
  8. May 23, 20228-K Entered a material agreement; Change to shareholders' rights; Bylaws or fiscal year changed40
  9. May 10, 20228-K Results of operations41
  10. Apr 12, 20228-K Listing notice or transfer42
  11. Mar 31, 20228-K Results of operations43
  12. Mar 31, 20228-K Other events44
  13. Oct 1, 2014New chief executive Susan Molineaux becomes CEO13
  14. Mar 9, 2010Founded Calithera Biosciences, Inc. is founded2

Calendar

When it reported results

  1. Nov 14, 2022Reported quarterly or annual results35
  2. Aug 15, 2022Reported quarterly or annual results37
  3. May 10, 2022Reported quarterly or annual results41
  4. Mar 31, 2022Reported quarterly or annual results43
  5. Nov 9, 2021Reported quarterly or annual results45
  6. Oct 19, 2021Reported quarterly or annual results46

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

116 filings to the SEC since October 2021: 2 annual reports, 4 quarterly reports, 18 major events, 50 insider forms, 16 large holders, 26 other. The latest 20:

  1. Jun 15, 2023CT ORDER EDGAR
  2. Jun 5, 2023DEFM14A EDGAR
  3. May 26, 2023SC 13D/A EDGAR
  4. May 26, 20234 EDGAR
  5. May 26, 2023PREM14A EDGAR
  6. May 22, 2023DEFA14A EDGAR
  7. Mar 31, 202310-K EDGAR
  8. Mar 17, 2023EFFECT EDGAR
  9. Mar 14, 202315-12G EDGAR
  10. Mar 14, 2023S-8 POS EDGAR
  11. Mar 14, 2023S-8 POS EDGAR
  12. Mar 14, 2023S-8 POS EDGAR
  13. Mar 14, 2023S-8 POS EDGAR
  14. Mar 14, 2023S-8 POS EDGAR
  15. Mar 14, 2023S-8 POS EDGAR
  16. Mar 14, 2023S-8 POS EDGAR
  17. Mar 14, 2023S-8 POS EDGAR
  18. Mar 14, 2023S-8 POS EDGAR
  19. Mar 14, 2023POS AM EDGAR
  20. Feb 14, 2023SC 13G/A EDGAR

The 116 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

7 open-market trades by officers, directors and large owners since October 2021: 3 buys and 4 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jan 27, 2023PAKIANATHAN DEEPIKADirectorSale121,333$0.39$47.3KForm 4
Nov 11, 2021Orford KeithDirectorSale48,190$0.88$42.4KForm 4
Nov 10, 2021Orford KeithDirectorSale30,000$0.86$25.8KForm 4
Nov 10, 2021Molineaux SusanPRESIDENT & CEOBuy100,000$0.85$85.0KForm 4
Nov 10, 2021DRACHMAN JONATHAN GDirectorBuy200,000$0.86$172.0KForm 4
Nov 10, 2021Molineaux ChristopherSR. VP, DEVELOPMENTBuy100,000$0.85$85.0KForm 4
Nov 9, 2021Orford KeithDirectorSale51,810$0.84$43.5KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Calithera Biosciences, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCalithera Biosciences, Inc.1
  • CIK0001496671
  • Employer ID (EIN)27-23663291
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business address343 Oyster Point Blvd #200, South San Francisco, CA 940801
  • Phone650-870-10001
  • Shares outstanding4,872,497 as of Mar 24, 20234
  • Public float$11.5M as of Jun 30, 20224
  • On EDGAR sinceJul 16, 20101
  • Filings530 in all: 4 (218), 8-K (83), SC 13G/A (43), 3 (26), 10-Q (25), SC 13G (17), 424B5 (14), DEFA14A (12)1
    All 39 form types

    10-K (9), S-8 (9), S-8 POS (9), DEF 14A (8), CT ORDER (6), CORRESP (5), D (5), EFFECT (5), SC 13D/A (5), UPLOAD (4), S-1/A (3), S-3 (3), SC 13D (3), 10-K/A (1), 15-12G (1), 25-NSE (1), 3/A (1), 4/A (1), 424B4 (1), 8-A12B (1), ARS (1), CERTNAS (1), D/A (1), DEFM14A (1), DRS (1), NT 10-Q (1), POS AM (1), POS EX (1), PRE 14A (1), PREM14A (1), S-1 (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2023
    Quarterly report (10-Q) Nov 14, 2022
    Proxy statement (DEF 14A) Apr 20, 2022
    Latest 8-K (8-K) Jan 25, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
    SEC EDGAROther events
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54